| 摘要 |
The present invention relates to compounds of general formula I, (I) wherein the group R1 is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR 1) and modulate its activity. The compounds are suitable for the treatment and prevention of diseases which can be influenced by this receptor; metabolic diseases, such as diabetes, more specifically type 2 diabetes mellitus, and conditions associated with the disease, including insulin resistance, obesity, cardiovascular disease and dyslipidemia. |
